FLAG-003 / FLAG Therap - LARVOL DELTA

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) (GlobeNewswire) - "FLAG Therapeutics...announced preclinical data from the company’s lead program, FLAG-003, an investigational small molecule therapy for the treatment of diffuse intrinsic pontine glioma (DIPG) and glioblastoma multiforme (GBM). Data from this study, which was conducted by researchers from Dana-Farber Cancer Institute, showed that single agent FLAG-003 resulted in potent anti-tumor activity in all eight DIPG cell lines tested....These data were presented at the recent 21st International Symposium on Pediatric Neuro-Oncology (Abstract/Poster DIPG-68)....FLAG Therapeutics conducted a successful Type B meeting with the FDA regarding FLAG-003 and intends to file an Investigational New Drug (IND) application in the fourth quarter of 2024 and to initiate Phase 1 clinical studies in DIPG in early 2025."

FDA event • IND • New P1 trial • Preclinical • Diffuse Intrinsic Pontine Glioma

FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG) (GlobeNewswire) - "FLAG Therapeutics, Inc., announced today that FLAG-003...for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG)...has been granted Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA)."

FDA event • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioma • Oncology • Solid Tumor

Radiosynthesis and evaluation of [C]AG-488, a dual anti-angiogenetic and anti-tubulin PET ligand. (PubMed, Bioorg Med Chem Lett) - "AG-488 aka FLAG-003 is a novel ligand with established antiangiogenetic properties via activation of receptor thymidine kinase (RTK) and anti-tubulin properties in tumor cells...However, blocking studies with antitubulin and RTK agent HD-800 and microtubule depolymerizing agent MPC-6827 show increased binding of [C]AG-488 in brain. The pattern of tracer binding in blocking conditions is similar to the baseline conditions. The higher binding may be due to the increased plasma uptake of radiotracer or the formation of more free tubulins due to microtubule dynamic instability during the blocking conditions."

Journal • Brain Cancer • Breast Cancer • Glioblastoma • Oncology • Solid Tumor